Dr. Maya Gambarin-Gelwan, MD

Dr. Gambarin-Gelwan practices at Memorial Sloan Kettering Cancer Center in New York, New York, part of Memorial Sloan Kettering Cancer Center.

Dr. Gambarin-Gelwan's NPI, 1932144730, was assigned on June 17, 2006. Dr. Gambarin-Gelwan graduated from Icahn School Of Medicine At Mount Sinai in 1998. Dr. Gambarin-Gelwan holds New York license 214609.

Dr. Gambarin-Gelwan's primary practice is Memorial Sloan Kettering Cancer Center, at 1275 York Avenue, New York, NY 10065.

Dr. Gambarin-Gelwan's primary practice is Memorial Sloan Kettering Cancer Center in New York, New York, part of Memorial Sloan Kettering Cancer Center. The medical group on file is Memorial Sloan Kettering Cancer Center.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Gambarin-Gelwan practices. Vendor and product names are available with a free account.

Gastroenterology is Dr. Gambarin-Gelwan's primary specialty in the NPI Registry, under taxonomy code 207RG0100X. Dr. Gambarin-Gelwan is board certified in gastroenterology by the American Board of Internal Medicine. Dmand AI has Dr. Gambarin-Gelwan's licenses on file in 3 states: New York, Florida and New Jersey.

Dmand AI lists cirrhosis of the liver, colonoscopy, fatty liver, hepatitis c and upper GI endoscopy among the conditions Dr. Gambarin-Gelwan treats.

CMS data shows 636 Medicare services from Dr. Gambarin-Gelwan across 9 procedure codes in 2024, for 333 Medicare patients. Medicare paid $47,995 for them.

CMS counts 333 Medicare patients who saw Dr. Gambarin-Gelwan in 2024. The largest group is 65 to 74, with 178 patients. 75% of them have high blood pressure, and 75% have high cholesterol. 18% are also on Medicaid. Their average risk score is 2.54, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Gambarin-Gelwan's median patient age at 70, with 50% women.

In 2024, Dr. Gambarin-Gelwan wrote 670 Medicare Part D claims for 120 patients. 86% of them were for generic drugs. CMS names the drug for 589 of them, across 14 drugs with 11 or more claims each, at $238,331 in total drug cost. In 2023, CMS named 377 claims across 11 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 79 out of 100 for Dr. Gambarin-Gelwan for performance year 2024, reported as part of a group. Dr. Gambarin-Gelwan accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Gambarin-Gelwan as offering telehealth. CMS counts 28 procedures of upper gastrointestinal (gi) endoscopy for acid reflux by Dr. Gambarin-Gelwan, more than 55% of the clinicians it reports for that procedure.

Dmand AI links 15 papers to Dr. Gambarin-Gelwan, published from 2005 to 2021. 2020 was the busiest year, with 2. The most frequent topics are Carcinoma, Hepatocellular, Hepacivirus and Hepatitis C, Chronic. Dr. Gambarin-Gelwan has published most often in Clin Transplant. Dr. Gambarin-Gelwan's most frequent co-authors are Arun Jesudian, MD, Brandon Aden, MD and Peter J. Allen, MD.

Dmand AI lists 1 award for Dr. Gambarin-Gelwan, most recently CMS Stage 1 EHR in 2011.

Dr. Gambarin-Gelwan graduated from Icahn School Of Medicine At Mount Sinai in 1998. Dr. Gambarin-Gelwan is a member of ACP.

Dr. Gambarin-Gelwan is in network with 11 carriers, including Excellus BlueCross BlueShield, United Healthcare and Blue Cross Blue Shield of Massachusetts. PPO plans come from the most carriers, 7. Check the plan with the practice before a visit.